Kazia Therapeutics has entered into a strategic partnership with QIMR Berghofer, committing $1.4 million upfront to access an innovative AI-integrated platform aimed at developing epigenetic drugs targeting SETDB1. This group of proteins is known for silencing tumor suppressor genes, and by inhibiting SETDB1, the platform seeks to restore immune signaling in tumors resistant to current immunotherapies, including checkpoint inhibitors. The collaboration has already yielded a lead candidate, MSETC, a selective bicyclic peptide designed to target a novel SETDB1 complex associated with disease.

The significance of this development lies in its potential to enhance therapeutic options for cancer patients facing resistance to existing treatments. By focusing on SETDB1, Kazia aims to address a critical mechanism of immune evasion in tumors. The platform not only promises to deliver MSETC but also has a pipeline of follow-up candidates exhibiting strong selectivity and intracellular targeting capability. This approach could redefine treatment paradigms by directly targeting chromatin-level immune regulation, a novel strategy that complements Kazia’s existing efforts with paxalisib, a PI3K/Akt/mTOR pathway inhibitor.

The implications of this partnership extend to the broader landscape of cancer research and drug development. By integrating epigenetic modulation with existing therapeutic strategies, Kazia is positioning itself to tackle cancer from multiple biological angles. This multifaceted approach could significantly shorten drug development timelines and enhance the efficacy of combination therapies, ultimately improving patient outcomes in oncology. As the field moves towards more personalized and targeted treatments, Kazia’s focus on SETDB1 could serve as a pivotal shift in how we approach cancer therapy.

Source: fiercebiotech.com